AU2019244477A1 - Farber disease markers and uses thereof - Google Patents

Farber disease markers and uses thereof Download PDF

Info

Publication number
AU2019244477A1
AU2019244477A1 AU2019244477A AU2019244477A AU2019244477A1 AU 2019244477 A1 AU2019244477 A1 AU 2019244477A1 AU 2019244477 A AU2019244477 A AU 2019244477A AU 2019244477 A AU2019244477 A AU 2019244477A AU 2019244477 A1 AU2019244477 A1 AU 2019244477A1
Authority
AU
Australia
Prior art keywords
subject
level
mhcii
cdllb
farber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019244477A
Other languages
English (en)
Inventor
Christine COQUERY
Brante SAMPEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Aceragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aceragen Inc filed Critical Aceragen Inc
Publication of AU2019244477A1 publication Critical patent/AU2019244477A1/en
Assigned to ACERAGEN, INC. reassignment ACERAGEN, INC. Request for Assignment Assignors: ENZYVANT THERAPEUTICS GMBH
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2019244477A 2018-03-27 2019-03-22 Farber disease markers and uses thereof Abandoned AU2019244477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
US62/648,775 2018-03-27
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Publications (1)

Publication Number Publication Date
AU2019244477A1 true AU2019244477A1 (en) 2020-06-25

Family

ID=66530353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019244477A Abandoned AU2019244477A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Country Status (15)

Country Link
EP (1) EP3775924A1 (https=)
JP (2) JP2021516757A (https=)
KR (2) KR20200136367A (https=)
CN (2) CN111971562A (https=)
AU (1) AU2019244477A1 (https=)
BR (1) BR112020016435A2 (https=)
CA (1) CA3090354A1 (https=)
CL (1) CL2020002105A1 (https=)
CO (1) CO2020010043A2 (https=)
IL (2) IL311212A (https=)
MX (1) MX2020008377A (https=)
PH (1) PH12020551206A1 (https=)
RU (1) RU2020119065A (https=)
SG (1) SG11202007508TA (https=)
WO (1) WO2019186272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152532A1 (en) * 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
US20240180982A1 (en) * 2021-03-29 2024-06-06 University College Cardiff Consultants Limited Modified adenovirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995001164A1 (en) 1993-06-30 1995-01-12 Genentech, Inc. Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CA2905449C (en) 2013-03-14 2024-09-10 Icahn School Of Medicine At Mount Sinai THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Also Published As

Publication number Publication date
CN111971562A (zh) 2020-11-20
RU2020119065A (ru) 2022-04-27
JP2021516757A (ja) 2021-07-08
WO2019186272A1 (en) 2019-10-03
EP3775924A1 (en) 2021-02-17
CN118112249A (zh) 2024-05-31
IL276420A (en) 2020-09-30
JP2023159164A (ja) 2023-10-31
CA3090354A1 (en) 2019-10-03
MX2020008377A (es) 2020-09-25
PH12020551206A1 (en) 2021-04-19
BR112020016435A2 (pt) 2020-12-15
SG11202007508TA (en) 2020-09-29
CL2020002105A1 (es) 2020-12-04
IL311212A (en) 2024-05-01
KR20200136367A (ko) 2020-12-07
CO2020010043A2 (es) 2020-11-10
KR20240111011A (ko) 2024-07-16

Similar Documents

Publication Publication Date Title
US20250170225A1 (en) Compositions and methods for treating farber disease
US6703486B2 (en) Peripheral nervous system specific sodium channels
CA2983004A1 (en) Methods for treating myeloproliferative disorders
JP2023159164A (ja) ファーバー病マーカーおよびその使用
AU2025202813A1 (en) Methods for treating Farber disease
CN103298482B (zh) 用于免疫耐受性诱导和免疫诊断的fviii肽
US20210199670A1 (en) Farber disease markers and uses thereof
US5863734A (en) Method of treatment for obsessive-compulsive disorder
WO2001046415A1 (en) Novel tachykinin-like polypeptides and use thereof
HK40105998A (en) Compositions and methods for treating farber disease
US20040213738A1 (en) CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
CN1307104A (zh) 一种新的多肽——人磷酸烯醇丙酮酸羧化酶81和编码这种多肽的多核苷酸

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ACERAGEN, INC.

Free format text: FORMER APPLICANT(S): ENZYVANT THERAPEUTICS GMBH

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted